Insider Transactions in Q4 2020 at Stoke Therapeutics, Inc. (STOK)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2020
|
Edward M. Md Kaye CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 28
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
149
-0.69%
|
$8,642
$58.73 P/Share
|
|
Dec 28
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+27.12%
|
$0
$0.6 P/Share
|
|
Dec 21
2020
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,365
-0.26%
|
$77,805
$57.93 P/Share
|
|
Dec 21
2020
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,365
+0.78%
|
$2,730
$2.19 P/Share
|
|
Dec 18
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
5,194
-100.0%
|
$311,640
$60.0 P/Share
|
|
Dec 18
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,015
-100.0%
|
$480,900
$60.0 P/Share
|
|
Dec 18
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,015
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 17
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
19,806
-79.22%
|
$1,188,360
$60.0 P/Share
|
|
Dec 17
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
41,985
-100.0%
|
$2,519,100
$60.0 P/Share
|
|
Dec 17
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,985
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-62.73%
|
$285,000
$50.85 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 27
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
12,152
-32.71%
|
$607,600
$50.0 P/Share
|
|
Nov 25
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
12,848
-25.7%
|
$642,400
$50.0 P/Share
|
|
Nov 24
2020
|
Apple Tree Partners Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 24
2020
|
Seth Loring Harrison |
BUY
Open market or private purchase
|
Indirect |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos |
SELL
Open market or private sale
|
Direct |
20,000
-70.66%
|
$920,000
$46.38 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.19 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$2,250,000
$45.0 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+35.58%
|
$50,000
$1.4 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
33,268
-68.43%
|
$1,363,988
$41.14 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,268
+49.55%
|
$133,072
$4.48 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
1,732
-74.21%
|
$67,548
$39.84 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,732
+42.6%
|
$6,928
$4.48 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-77.75%
|
$210,900
$37.29 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
35,000
-63.35%
|
$1,295,000
$37.7 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+49.57%
|
$140,000
$4.48 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
32,000
-44.66%
|
$1,216,000
$38.03 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+22.07%
|
$32,000
$1.4 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
5,851
-30.24%
|
$234,040
$40.0 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
5,851
+23.22%
|
$0
$0.6 P/Share
|
|
Oct 13
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
1,649
-10.89%
|
$65,960
$40.0 P/Share
|
|
Oct 13
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
1,649
+9.82%
|
$0
$0.6 P/Share
|
|
Oct 01
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-79.82%
|
$193,800
$34.6 P/Share
|
|
Oct 01
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|